Japan's ministry of health, labor and welfare approves csl and arcturus therapeutics' updated self-amplifying mrna covid-19 vaccine for protection against jn.1 strain, to be distributed in japan by meiji seika pharma

Approval underscores csl and arcturus therapeutics' commitment to delivering disruptive technologies to combat covid-19 and other respiratory viral diseases to protect public health kostaive®, the world's first self-amplifying mrna (sa-mrna) covid-19 vaccine, was approved for adults 18 years of age and older in november 2023 the updated sa-mrna covid-19 vaccine is tailored to protect against the jn.1 lineage of omicron subvariants meiji seika pharma, csl's exclusive partner in japan, will begin vaccine distribution in time for the october covid-19 vaccination campaign  csl and arcturus therapeutics' partnership delivers on the promise to advance innovative vaccine technology for viral respiratory diseases king of prussia, pa. and san diego , sept.
ARCT Ratings Summary
ARCT Quant Ranking